SCHEDULE: Polaris Partners Adjusts Camp4 Therapeutics Stake

Polaris Partners entities and associated individuals have amended their Schedule 13D filing to reflect a decrease in their aggregate beneficial ownership of Camp4 Therapeutics Corporation's common stock.

Summary

• This filing is an amendment (Amendment No. 2) to a Schedule 13D originally filed on October 22, 2024, and previously amended on September 11, 2025.
• The amendment is filed to update the aggregate percentage of Camp4 Therapeutics Corporation's common stock beneficially owned by the reporting persons.
• The decrease in ownership percentage is attributed to dilution caused by the Issuer's sales of additional shares of its Common Stock since the filing of Amendment No. 1.
• This resulted in a decrease of over one percent (1%) in the aggregate percentage ownership previously reported.
• The reporting persons include Polaris Management Co. VII, L.P., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners GP X, L.L.C., Polaris Partners X, L.P., Amir Nashat, Brian Chee, and Amy Schulman.
• Amir Nashat is noted as a member of Camp4 Therapeutics Corporation's board of directors.
• The total beneficial ownership reported by Amir Nashat is 3,932,251 shares, representing 6.3% of the class of securities.
• The percentage ownership is based on 62,753,200 shares of Common Stock outstanding as of August 12, 2026, as reported in the Issuer's Form 10-Q filed on August 13, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to a decrease in ownership percentage, indicating potential dilution or strategic adjustments by the reporting persons, without significant new positive or negative developments.

Negatives

• The aggregate percentage ownership of Camp4 Therapeutics Corporation's common stock by the reporting persons has decreased by over 1% due to dilution from the company's stock sales.
• This decrease in ownership percentage may indicate a reduced influence or strategic shift by the reporting entities.

Risks

• Dilution from the Issuer's sales of additional shares of its Common Stock has reduced the reporting persons' aggregate percentage ownership.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. It primarily reports on changes in beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are typically made by investors who acquire a significant stake (5% or more) in a public company. Amendments often reflect changes in ownership, strategic intentions, or responses to corporate events. The dilution mentioned suggests Camp4 Therapeutics may have recently raised capital or issued shares, a common practice for growth-stage companies, which can impact existing shareholders' percentage ownership.

Stakeholder Impact

• Shareholders may experience dilution in their ownership percentage due to the company's recent stock sales.
• Investors holding shares in Camp4 Therapeutics Corporation should be aware of the potential impact of ongoing share issuances on their stake.

Key Dates

Keywords

Schedule 13D, Beneficial Ownership, Camp4 Therapeutics, Polaris Partners, Stock Dilution, Amir Nashat, SEC Filing, Amendment